Business profile
Loading canonical business information.
About
Services
Products
Articles & research
Offers
Published by the business. Confirm current availability and terms with the business.
Browse productsPromotions
Published by the business. Confirm current availability and terms with the business.
Browse productsFrequently asked questions
Answers published by the business.
Published agent capabilities
Capabilities recorded in this listing. Their presence is not a live availability check.
AI-readable discovery
Read the structured business information and inspect the published discovery documents.
Machine-readable documents do not by themselves establish a live AI agent, checkout or business ownership.
Request a quote
Loading quote availability…
Sources
Report this listing
Tell us what needs reviewing. Removal requests are reviewed before any change is made.
Request removalProfile information
Publication, owner access and business registry verification are separate. Verification badges describe the checks completed; public references identify this listing.
Structured public business summary
REMAP-CAP Trial
REMAP-CAP Trial Home About REMAP-CAP About REMAP-CAP --> Background What is an adaptive trial? Pandemic Preparedness COVID-19 Response Publications The REMAP-CAP team The REMAP-CAP team --> Participating sites International Trial Steering Committee Data Safety Monitoring Board Partners Resources Resources --> Study Resources Current Protocol Documents Superseded Protocol Documents Statistical Analysis Plans Contact Us Menu Street Address City, State, Zip Phone Number A Randomised, Embedded, Multifactorial, Adaptive Platform Trial Your Custom Text Here Home About REMAP-CAP Background What is an adaptive trial? Pandemic Preparedness COVID-19 Response Publications The REMAP-CAP team Participating sites International Trial Steering Committee Data Safety Monitoring Board Partners Resources Study Resources Current Protocol Documents Superseded Protocol Documents Statistical Analysis Plans Contact Us REMAP-CAP A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia 27,634 Patient randomisations 16,399 Total patients 240 Active sites SPECIAL UPDATE New trial results: Oseltamivir in critically ill patients with influenza infection.
Global
Business nature
- Primary business nature
- Not provided
- Customer market
- Not provided
Operating hours
Hours not provided.
Categories
- Other Businesses & Services (primary)
Public contacts
- Public email: communications@remapcap.org
- Public phone: +61 3 9903 0247
- x: https://x.com/remap_cap
Declared AI capabilities
- Online support — Detected from public website navigation or discovery metadata.
Directory status
Registry verification: Not Registry Verified
Directory score: 80
Public source evidence
- REMAP-CAP Trial
- Response to COVID-19 pandemic — REMAP-CAP Trial
- Background — REMAP-CAP Trial
- Study Resources — REMAP-CAP Trial
- Partners — REMAP-CAP Trial
- Data Safety Monitoring Board — REMAP-CAP Trial
- Statistical Analysis Plans — REMAP-CAP Trial
- Contact Us — REMAP-CAP Trial